Chemoprevention of Gastric Cancer: Metformin |
Young Il Kim, Soo Jeong Cho |
Center for Gastric Cancer, National Cancer Center, Goyang, Korea. crystal522@ncc.re.kr |
위암의 화학 예방 요법: 메트포르민 |
김영일, 조수정 |
국립암센터 위암센터 |
Received: 10 October 2017 • Revised: 8 November 2017 • Accepted: 9 November 2017 |
Abstract |
Metformin is a first-line anti-diabetic drug that has been widely used in patients with type 2 diabetes. Many population-based epidemiologic studies have shown that metformin treatment is associated with decreased risk for various cancers. Recent epidemiologic studies showed that the use of metformin was associated with a reduction in gastric cancer risk, especially in patients with type 2 diabetes who used metformin for long periods of time (>2~3 years). Currently, there are no registered clinical trials investigating the anti-cancer effect of metformin in gastric cancer; hence, further well-designed clinical trials are required. Herein, we review the literature regarding the use of metformin for the prevention of gastric cancer. |
Key Words:
Chemoprevention; Metformin; Stomach neoplasms |
|